1. Home
  2. PTGX

PTGX

Protagonist Therapeutics Inc.

Logo Protagonist Therapeutics Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-16-2024 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.

Founded: 2006 Country:
United States
United States
Employees: N/A City: NEWARK
Market Cap: 1.6B IPO Year: 2016
Target Price: $38.60 AVG Volume (30 days): 691.1K
Analyst Decision: Strong Buy Number of Analysts: 6
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.39 EPS Growth: N/A
52 Week Low/High: $13.72 - $33.34 Next Earning Date: 05-02-2024
Revenue: $60,000,000 Revenue Growth: 125.73%
Revenue Growth (this year): 159.25% Revenue Growth (next year): -9.84%

Share on Social Networks: